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Dialysis-dependent renal failure at diagnosis continues to be
associated with very poor outcome in multiple myeloma –
response to Murphy et al
The study by Murphy et al supports the observation made
by several groups regarding the benefit of the novel agents in
both young and elderly patients affected by multiple
myeloma (MM) (Kumar et al, 2008; Ludwig et al, 2008;
Turesson et al, 2010; Pozzi et al, 2013). Their single institu-
tion data collected over 18 years in 262 patients shows an
improvement in overall survival (OS) starting from 1995
with an OS not yet reached in the period 2007–2012, after
the introduction of bortezomib in their clinical practice.
However the study clearly highlights renal insufficiency as a
very poor prognostic factor, with a median OS shorter than
1 year in patients requiring dialysis.
In the past few years many attempts have been made to
classify and stratify patients based on various refined biologi-
cal characteristics, however, as clearly stated here, the clinical
presentation, particularly organ damage, still represents a
negative prognostic factor that not even modern medicine
has been able to overcome. The introduction of the Interna-
tional Staging System Criteria (ISS) (Greipp et al, 2005) only
indirectly takes renal function into account, while the Durie
and Salmon Criteria differentiates stage ‘A’ and ‘B’ MM
based on kidney damage (Durie & Salmon, 1975). However
Durie-Salmon ‘B’ stage is based on a creatinine cut-off point
of 177 lmol/l and it is unable to better differentiate between
moderate and severe impairment of renal damage requiring
dialysis. It is also unable to predict the response to the
treatment and reversibility of the organ damage, between
possibly transitory kidney impairment due to dehydration,
hyperuricaemia and hypercalacemia, and cast nephropathy.
In this subset of MM patients it would be beneficial to
introduce further parameters in the staging system (i.e. glo-
merular filtrate; type of light chain) in order to better stratify
the risks and prevent treatment-related toxicity. For this rea-
son, ad hoc clinical trials for this group of patients are
strongly needed (Haynes et al, 2012).
Finally, the Murphy study highlights the selection of
patients enrolled in clinical trials and the necessity to evaluate
the survival in the population of every day clinical practice,
together with the need to develop high resolution analysis
from data collected by cancer registers.
Moreover, early diagnosis, compared with late or misdiag-
nosis, especially for light chains MM, is mandatory to pre-
vent severe organ damage.
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